Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.
about
Incidence and risk factors of venous thromboembolism (VTD) in patients with amyloidosisFifty years of melphalan use in hematopoietic stem cell transplantationUpdate on treatment of light chain amyloidosisImproved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research StudyIndependent predictors of survival in primary systemic (Al) amyloidosis, including cardiac biomarkers and left ventricular strain imaging: an observational cohort study.Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score.Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operativAbnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death.High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement.Al amyloidosisA prospective study of nutritional status in immunoglobulin light chain amyloidosis.Chronic myopathy due to immunoglobulin light chain amyloidosis.Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego).Incidence, diagnosis and prognosis of cardiac amyloidosis.Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis.Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center.New and developing therapies for AL amyloidosis.High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.Diffuse large B-cell lymphoma mimicking cardiac amyloidosis.Autologous stem cell transplant for Al amyloidosis.AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation.Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis.A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time.Predictors of early treatment failure following initial therapy for systemic immunoglobulin light-chain amyloidosis.Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis.Amyloid disease and the danger of late diagnosis.Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis
P2860
Q24815899-6CBA7E55-658B-4700-8002-87451BCAC691Q26824498-62A07355-2869-4C72-901D-B3486357445DQ26829735-A55137C9-96D9-4365-B955-8AAB24F3CD99Q30278687-2DF4AF9F-1EF6-4A20-93F9-29524E0621C9Q33698796-C2B534B6-637C-4CD4-9FCA-5992FDE0B74CQ34450910-90144E78-A18C-4532-A67A-66507C4A8E72Q35571048-D5A05C68-62F8-41EE-8646-C1BF949C2628Q35579434-4F2FE1D7-299D-4AA1-B347-FCC90ECDB169Q35750326-05AD89A4-5263-4F9A-B19A-18FD49DE0DBBQ36392233-7CAF3A63-F566-4096-9611-64C33EDE7553Q36498408-187B70B0-AADB-4F22-86DD-F52461B73BC5Q36716131-2890393B-CF47-4988-88BF-99D1EA8B742FQ36779777-806AB2DB-12B0-4731-A3FF-FFF2D6F17871Q37045900-C378C2BE-578C-4D04-AB7A-3BA460E24280Q37399628-1801DDF3-0F88-4FD1-A1DC-5445F351E15FQ37570615-61A0D864-5120-48CA-B455-0E41027C8093Q37904673-720D596D-B309-4D05-B24E-5512108C36C1Q38100588-1CA8E906-5546-403B-BB4B-1D0C77879D28Q38779623-FB97EC01-4073-454C-A441-EEE75E2794C1Q41021929-295EFAE7-3F4C-4A79-B5A3-CF0CEF845968Q42072909-94D86B92-F490-4986-8F76-5A9F1ED193D4Q42179759-DFEF05F0-3F92-4AD2-84FA-4584E2CBDCB0Q44199471-C5DF4685-DA4C-4013-B483-6AECF16895B7Q44248482-F5458D2A-B16D-4C95-ABBF-595F5DDB36C6Q47096627-65EBAE58-18DA-473C-B84F-BC0F0B78838FQ48139614-1CBDE639-E1C8-4758-A453-97EC18760888Q52957346-4A90FE2E-E567-485C-A856-8CAFE41C8B48Q53504425-45E46655-CE87-4D57-9BE8-E81B85C0F52CQ55443290-363FBAF1-6C9F-4B97-9246-0124A1645743Q58125083-C75288A0-B412-4FD2-8B0D-340BEC4A1A3F
P2860
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Eligibility for hematopoietic ...... rognostic factor for survival.
@en
Eligibility for hematopoietic ...... rognostic factor for survival.
@nl
type
label
Eligibility for hematopoietic ...... rognostic factor for survival.
@en
Eligibility for hematopoietic ...... rognostic factor for survival.
@nl
prefLabel
Eligibility for hematopoietic ...... rognostic factor for survival.
@en
Eligibility for hematopoietic ...... rognostic factor for survival.
@nl
P2093
P1476
Eligibility for hematopoietic ...... rognostic factor for survival.
@en
P2093
A Dispenzieri
D R Larson
P R Greipp
T E Witzig
T M Therneau
P304
P356
10.1200/JCO.2001.19.14.3350
P407
P577
2001-07-01T00:00:00Z